Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 0.32% in last session and finished the day at $6.20. Traded volume was 4.92million shares in the last session and the average volume of the stock remained 5.60million shares. The beta of the stock remained -0.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Abbott Laboratories Inc reported (NYSE:ABT) better-than-expected quarterly earnings on cost controls, but sales came in slightly below Wall Street expectations. The company on April 16 said it earned $375 million, or 24 cents per share in the first quarter. That compared with $544 million, or 34 cents per share, in the year-ago quarter, when Abbott took charges for licensing and acquisitions. Abbott Laboratories (NYSE:ABT) dropped -0.57 percent to $38.71 Monday on volume of 6.92million shares. The intra-day range of the stock was $38.45 to $38.99. Abbott Laboratories (NYSE:ABT) has a market capitalization of $59.73billion.

UnitedHealth Group, Inc. (NYSE:UNH) the nation’s largest health insurer, reported a first-quarter earnings decline Thursday, blaming ObamaCare taxes, Medicare Advantage cuts and Gilead Sciences’ costly hepatitis C drug. UnitedHealth Group Inc. (NYSE:UNH)’s stock on Apr 21, 2014 reported a decrease of -1.10% to the closing price of $74.95. Its fifty two weeks range is $58.03 -$83.32. The total market capitalization recorded $74.14billion. The overall volume in the last trading session was 6.91million shares. In its share capital, UNH has 989.19million outstanding shares.

U.S. shares in AstraZeneca PLC (ADR) (NYSE:AZN) rose Monday on speculation the company had been approached by rival drug maker Pfizer Inc. about takeover talks. On Monday, shares of AstraZeneca plc (ADR) (NYSE:AZN) advanced 8.84% to close the day at $69.10. Company return on investment (ROI) is 9.00% and its monthly performance is recorded as 6.55%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly revenue growth is 11.54%.